Google快讯 - lung cancer

	lung cancer 实时更新 ⋅ 2024年9月8日
	新闻
	Novel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was ... AstraZeneca These insights are critical to advancing our understanding of how we can more precisely identify patients with non-small cell lung cancer who may ... 标记为不相关
	Artificial intelligence method transforms gene mutation prediction in lung cancer - EurekAlert! EurekAlert! The research was presented today at the IASLC 2024 World Conference on Lung Cancer by Professor Wenhua Liang, from the China State Key Laboratory of ... 标记为不相关
	Ivonescimab Tops Pembro in Advanced PD-L1-Positive NSCLC - Medscape Medscape ... Lung Cancer in San Diego. Zhou is president-elect of the IASLC ... Why Lung Cancer Screening Is Not for Everyone · Invasive Procedures and ... 标记为不相关
	Risk Adjusted Net Present Value: What is the current valuation of iTeos Therapeutics's Belrestotug Pharmaceutical Technology Belrestotug is a monoclonal antibody commercialized by iTeos Therapeutics, with a leading Phase II program in Non-Small Cell Lung Cancer. 标记为不相关
查看更多结果 | 修改此快讯

您收到此电子邮件是因为您订阅了Google快讯。 退订 | 查看您所有的快讯

以RSS Feed的形式接收此快讯

发送反馈